D-0102-2019 Class II Terminated
FDA drug recall D-0102-2019 was initiated by Teva Pharmaceuticals USA on Aug 6, 2018 and is designated Class II. Reason for recall: Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release. The recall status is terminated (terminated Feb 13, 2020).
Recall Details
- Product Type
- Drugs
- Report Date
- Oct 31, 2018
- Initiation Date
- Aug 6, 2018
- Termination Date
- Feb 13, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
Product Description
PIO&METFORMIN 15/1000 mg Tab 1 (Pioglitazone and Metformin XT) tablets, Takeda Brand Name: Actoplus Met XR (Pioglitazone and metformin HCl extended -release) tablets, 15 mg/1000 mg, packaged in a fiber drum, Application Holder Takeda Pharmaceuticals, U.S.A. Inc. One Takeda Parkway, Deerfield, IL 60015
Reason for Recall
Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.
Distribution Pattern
Product was distributed throughout the United States. Bulk product was distributed to Takeda, Deerfield, IL and may have been further distributed.
Code Information
Bulk Lot no 1250668, 15 mg/1000 mg Bulk product No # 1274150, no NDC Codes, bulk exp. date 05/2020 & 10/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0102-2019
- openFDA file date
- Oct 23, 2026
- Loaded by RegDataLab
- Oct 24, 2026